Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 12/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25623356 | 1.00 | KCNA5 (0.37) | KCNA5MAPTRAB9ATACR3F2 | |
| SCHEMBL24036741 | 0.88 | KDM4E (0.38) | KCNA5MAPTRAB9A | |
| SCHEMBL25753665 | 0.88 | KDM4E (0.38) | KCNA5MAPTRAB9A | |
| SCHEMBL25753660 | 0.86 | MEN1 (0.40) | — | |
| SCHEMBL25623349 | 0.86 | MEN1 (0.40) | — | |
| SCHEMBL25753673 | 0.86 | WDR5 (0.43) | — | |
| SCHEMBL25753676 | 0.86 | KCNA5 (0.47) | KCNA5MAPT | |
| SCHEMBL24036985 | 0.86 | KCNA5 (0.47) | KCNA5MAPT | |
| SCHEMBL24036979 | 0.86 | WDR5 (0.43) | — | |
| SCHEMBL31367054 | 0.85 | KCNQ3 (0.34) | KCNA5MAPTRAB9ATACR3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | KCNA5 1043/4885MAPT 3157/4885RAB9A 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.